What is the difference between the Fibrosis-4 (FIB-4) index and the NASH/FibroSure test for hepatic steatosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FIB-4 vs NASH/FibroSure: Key Differences for Hepatic Steatosis Assessment

FIB-4 is a simple, free calculator using age and routine lab values (AST, ALT, platelets) that assesses fibrosis stage, while FibroSure (also called FibroTest) is a proprietary blood test measuring specific serum biomarkers that also stages fibrosis—neither test directly measures hepatic steatosis itself.

What Each Test Actually Measures

FIB-4 Index

  • Purpose: Stages liver fibrosis (scarring), NOT steatosis (fat accumulation)
  • Components: Age, AST, ALT, platelet count
  • Cost: Free calculation
  • Validated cutoffs: <1.45 rules out advanced fibrosis (F3-F4) with 94.7% negative predictive value; >3.25 confirms advanced fibrosis with 82.1% positive predictive value 1
  • Performance: Correctly classifies 72.8% of patients when using these thresholds 1

FibroSure/FibroTest

  • Purpose: Also stages liver fibrosis, NOT steatosis
  • Components: Proprietary panel of serum biomarkers (specific proteins involved in fibrosis)
  • Cost: Commercial test requiring payment
  • Concordance with FIB-4: When FIB-4 values are <1.45 or >3.25, FibroSure agrees 92.1% and 76% of the time, respectively 1

Critical Distinction: Neither Test Measures Steatosis

Both tests assess fibrosis stage, which is the amount of liver scarring and proximity to cirrhosis—not the degree of fat accumulation (steatosis). 2 For steatosis assessment, you need different tools:

  • Controlled Attenuation Parameter (CAP) on FibroScan identifies advanced steatosis in 89.7% of biopsy-confirmed cases 3
  • NAFLD Liver Fat Score (NLFS) has only 58-61% accuracy for steatosis 4

Guideline-Recommended Approach

FIB-4 is recommended as the first-line assessment tool over FibroSure based on its simplicity and zero cost, despite FibroSure having comparable accuracy. 2 The 2023 AGA guidelines explicitly state that while FIB-4 does not outperform proprietary biomarkers like FibroSure, it is preferred for initial risk stratification 2.

Sequential Testing Algorithm (Per 2023 AGA Guidelines)

  1. Calculate FIB-4 first in all patients with NAFLD/MASLD
  2. If FIB-4 <1.45: Low risk, reassess in 2-3 years
  3. If FIB-4 1.45-3.25: Indeterminate zone—proceed to elastography (FibroScan) or consider FibroSure if elastography unavailable 2
  4. If FIB-4 >3.25: High risk, refer to hepatology

Performance Comparison in Real-World Practice

The 2025 AASLD systematic review found both tests provide "small-to-moderate change in pretest probability" for diagnosing advanced fibrosis 5. Key limitations:

  • FIB-4 feasibility issue: In real-world diabetes clinics, only 36% of patients had complete lab data needed to calculate FIB-4 (AST/ALT frequently missing) 6
  • Both tests have significant false rates: When compared to liver biopsy, false positive rates of 36-39% and false negative rates of 15-18% for advanced fibrosis 7
  • FibroScan combined with FIB-4 achieves only 68.9% concordance with liver biopsy even when using society-recommended thresholds 3

Common Pitfalls to Avoid

  1. Don't use either test to diagnose steatosis—they measure fibrosis only
  2. Don't skip FIB-4 and go straight to FibroSure—guidelines prioritize the free test first 2
  3. Don't trust a single test in the indeterminate zone (FIB-4 1.45-3.25)—this requires additional testing with elastography or alternative biomarkers
  4. Don't assume normal FIB-4 means no disease—it only rules out advanced fibrosis, not early-stage disease or steatosis

When to Consider FibroSure Over FIB-4

FibroSure may be appropriate as a secondary assessment when:

  • Elastography is unavailable 2
  • FIB-4 falls in the indeterminate range (1.45-3.25)
  • Routine liver enzymes are not available for FIB-4 calculation

The bottom line: Use FIB-4 first for fibrosis risk stratification due to cost and accessibility, reserving FibroSure for situations where elastography is unavailable and FIB-4 is indeterminate. For actual steatosis assessment, you need imaging-based tools like CAP on FibroScan, not either of these blood tests.

References

Research

Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.